IFNG and head and neck cancer: TLR2 agonists (Pam3CSK4 and LTA) modestly increased PD-L1 only in the high-TLR2 line, MDA-MB-231, and this effect was amplified by IFN-γ, consistent with prior findings in head and neck cancer [36,37].